SCHEMBL1156574

SCHEMBL1156574

O=COC(Cl)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
CYP2D6 P10635 1/20 0.39
KMT2A Q03164 1/20 0.38
SRC P12931 1/20 0.34
LMNA P02545 4/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
DPP4 P27487 2/20 0.33
TP53 P04637 1/20 0.33
MAPK1 P28482 1/20 0.33
GLS O94925 1/20 0.33
F2 P00734 1/20 0.33
CYP2A6 P11509 1/20 0.33
HPGD P15428 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28650756 0.77 TSHR (0.44) TSHRLMNAALDH1A1MAPTDPP4
SCHEMBL3955535 0.76 CYP2D6 (0.42) TSHRCYP2D6KMT2ASRCLMNA
SCHEMBL858 0.76 CYP2D6 (0.42) TSHRCYP2D6KMT2ASRCLMNA
Hydrochloric Acid SCHEMBL10708013 0.74 HTT (0.44) TSHRCYP2D6KMT2ALMNAMAPK1
SCHEMBL5517002 0.74 CYP2D6 (0.41) TSHRCYP2D6KMT2ASRCLMNA
SCHEMBL4386400 0.73 KMT2A (0.42) TSHRCYP2D6KMT2ASRCLMNA
SCHEMBL959684 0.73 DPP4 (0.44) CYP2D6KMT2ADPP4GLSF2
SCHEMBL7052526 0.73 CYP2D6 (0.39) TSHRCYP2D6KMT2ASRCLMNA
SCHEMBL12555585 0.73 CYP2D6 (0.44) TSHRCYP2D6KMT2ASRCLMNA
SCHEMBL96936 0.73 HCAR2 (0.47) CYP2D6KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0153006-B1 BENZOTRICYCLIC NITROGEN-CONTAINING DIONES AND A PROCESS FOR THE PRODUCTION THEREOF WARNER-LAMBERT COMPANY (US) 1988-07-06 EP claimed
EP-0153006-A1 Benzotricyclic nitrogen-containing diones and a process for the production thereof WARNER-LAMBERT COMPANY (US) 1985-08-28 EP claimed
US-4530929-A Tricyclic containing an imide group WARNER-LAMBERT COMPANY (US) 1985-07-23 US claimed
JP-58008005-A None JP disclosed
CN-112778398-A Liver-targeting drug, pharmaceutical composition thereof and application thereof 杜心赟 2021-05-11 CN disclosed
CN-106255681-B The method for being used to prepare substituted seromycin 先正达参股股份有限公司 2019-11-22 CN disclosed
US-10308605-B2 Proton pump inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-06-04 US disclosed
CN-109574825-A A kind of synthetic method of phenylacetic acid 江南大学 2019-04-05 CN disclosed
CN-108822053-A The method for being used to prepare substituted seromycin 先正达参股股份有限公司 2018-11-16 CN disclosed
CN-102712825-B Coating agent and coated article INNOVATIVE SURFACE TECHNOLOGIES, INC. (US) 2016-03-16 CN disclosed
EP-1696898-B1 ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS UNIV OHIO STATE RES FOUND (US) 2015-11-18 EP disclosed
WO-2003099787-A1 NOVEL PIPERIDINE COMPOUND TANABE SEIYAKU CO., LTD. (JP) 2003-12-04 WO disclosed
EP-1179529-A1 NOVEL HYDROXAMIC ACID DERIVATIVES Daiichi Fine Chemical Co., Ltd. (JP) 2002-02-13 EP disclosed
US-6284914-B1 HYDROXAMIC ACID DERIVATIVES FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 2001-09-04 US disclosed
US-6147114-A HYDROXAMIC ACID DERIVATIVES FROM TUMOR NECROSIS FACTOR CONVERTING ENZYME FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 2000-11-14 US disclosed
CN-1041730-C Process for preparing hydrogenated pyridine derivatives SANKYO CO (JP) 1999-01-20 CN disclosed
EP-0832875-A1 HIGHLY WATER-SOLUBLE METALLOPROTEINASE INHIBITOR FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1998-04-01 EP disclosed
CN-1074446-A Hydroxypyridine Derivatives SANKYO CO (JP) 1993-07-21 CN disclosed
CN-85103264-A 9a-azepine-9a-homoerythromycin derivative 1987-01-14 CN disclosed
JP-S588005-A REPELLENT FOR NOXIOUS INSECT EARTH CHEM CORP LTD 1983-01-18 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10308605-B2 Proton pump inhibitors HRH2, HRH4, HRH1 TSHR 171/4885CYP2D6 112/4885KMT2A 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.